ArticleBMC urology2026
A retrospective study comparing multimodal fusion biopsy and conventional cognitive fusion biopsy for diagnosing prostate cancer.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCognitive fusion targeted biopsy (cTB) is widely used in clinical practice. To advance beyond cTB, we developed a multimodal fusion targeted biopsy (mTB) system that integrates magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion technology. This study compares prostate cancer (PCa) detection rates between these two biopsy methods, assessing the clinical utility and diagnostic accuracy of our novel fusion technique.
methodOur technology combines MRI and TRUS using the VENUS multimodal image fusion ultrasound system, which automatically merges imaging data, creates 3D prostate models, and performs automated analysis of suspicious lesions to guide precise biopsy planning. We retrospectively analyzed 301 patients who underwent prostate biopsies at Wujin People’s Hospital in Changzhou City from January 2023 to December 2024. All patients received 12 core systematic biopsies (SBx). When suspicious lesions were found, additional targeted biopsies (TBx) were performed. We compared clinically significant prostate cancer (csPCa) and any PCa detection rates, as well as the number of biopsy-positive cores, between the mTB group (n = 152) and the cTB group (n = 149).
resultsCompared to cTB, mTB significantly increased the detection rates of csPCa (48.7% vs. 32.2%, p = 0.004) and any PCa (53.3% vs. 40.9%, p = 0.032). The proportion of csPCa among all PCa cases was also higher with mTB (91.4% vs. 78.7%, p = 0.032). Patients undergoing combined TBx and SBx had a higher percentage of positive cores with mTB than with cTB (35.8% vs. 26.2%, p < 0.001), whereas no significant difference was observed in patients undergoing SBx alone. Multivariable logistic regression analysis demonstrated that mTB significantly improved PCa detection compared to cTB (p = 0.008). Furthermore, the overall rate of postoperative complications was significantly lower in the mTB group (p = 0.029).
conclusionOur developed MRI-TRUS fusion technology markedly enhances detection of csPCa through precise intraoperative biopsy. Given its feasibility and accuracy, this technology holds strong potential for future clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.